CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 79 enrolled
Drug / intervention
Bevacizumab +2 moredrug
Likely dose
Bevacizumab 10mg/kgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00405938
NCT00405938Phase 2Completed
CompareCT.gov

A Phase II Trial of Open-Label Bevacizumab Administered With Anastrozole or Fulvestrant as First-Line Therapy in Postmenopausal Hormone Receptor- Positive Metastatic Breast Cancer (With Trastuzumab in HER2-Positive Patients)

SCRI Development Innovations, LLC·interventional·Posted Nov 30, 2006·Updated Nov 18, 2021

In Brief

A Phase 2 clinical trial evaluating Bevacizumab, Anastrozole, and 1 other intervention for Breast Cancer and Breast Neoplasms. Completed, enrolled 79 participants across 11 sites.

Detailed Summary

This is a phase II trial combining bevacizumab with either fulvestrant or anastrozole with trastuzumab in the treatment of metastatic breast cancer in postmenopausal women. It is hoped that these combinations will keep the cancer from growing and spreading further.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBreast Cancer, Breast Neoplasms
CountriesUnited States
CollaboratorsGenentech, Inc., AstraZeneca

Timeline

Phase 2CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedNov 30, 2006
Enrollment StartNov 1, 2006
Primary CompletionJun 1, 2010
Study CompletionJun 1, 2011
TodayJul 2, 2026
Enrollment to primary: 3.6 yearsPosted 19.6 years ago

Interventions

Bevacizumabdrug

Bevacizumab 10mg/kg IV every 2 weeks

Anastrozoledrug

anastrozole (1 mg orally daily)

Fulvestrantdrug

fulvestrant (500 mg IM on Day 1 of Cycle 1, followed by 250 mg IM of fulvestrant on Day 15 of Cycle 1. On Day 1 of Cycle 2 and the first day of all subsequent cycles thereafter, patients in this treatment arm will receive 250 mg IM of fulvestrant).